human fgf7 elisa kit  (R&D Systems)

Journal: Journal of Translational Medicine

Article Title: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter

doi: 10.1186/s12967-024-05085-y

Figure Lengend Snippet: Role of CAFs-derived FGF7 in ovarian cancer progression. A Concentration of FGF7 in the medium of different cell types quantified using enzyme-linked immunosorbent assay (ELISA). B Cell viability of HO8910 cells measured by CCK8 assay after neutralizing FGF7 in CAFs-CM. C Cell viability of A2780 cells measured by CCK8 assay after neutralizing FGF7 in CAFs-CM. D Cell invasion ability evaluated by Transwell assay after 48 h in HO8910 and A2780 cells (200 × magnification). E Cell viability of HO8910 cells treated with different doses of hFGF7 measured by CCK8 assay. F Cell viability of A2780 cells treated with different doses of hFGF7 measured by CCK8 assay. G Cell invasion ability assessed by Transwell assay after 48 h in HO8910 and A2780 cells treated with different doses of hFGF7 (200 × magnification). H Wound healing assay used to measure cell migration ability after treatment with hFGF7 for 24 h (100 × magnification). I Expression of epithelial-mesenchymal transition (EMT) markers in ovarian cancer (OC) cells treated with different doses of hFGF7 examined by western blotting. Results are presented as the mean ± SD of three independent experiments. ****P < 0.0001, *P < 0.05

Article Snippet: FGF7 levels in the supernatant of different groups were measured using a human FGF7 ELISA kit (R&D Systems, USA) following the manufacturer's instructions.

Techniques: Derivative Assay, Concentration Assay, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Transwell Assay, Wound Healing Assay, Migration, Expressing, Western Blot

Journal: Journal of Translational Medicine

Article Title: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter

doi: 10.1186/s12967-024-05085-y

Figure Lengend Snippet: Characterization and communication of CAFs in single cell level. A Uniform Manifold Approximation and Projection (UMAP) plot illustrating major cell populations, with dots colored to represent different cell types: T cells, epithelial cells, endothelial cells, cancer-associated fibroblasts (CAFs), myofibroblasts, NK cells, B cells or plasma cells, and monocytes. B Bar plot presenting the fractions of different sample types relative to the total cell count per cell type in the samples analyzed. C Two-dimensional projections demonstrating input–output signal intensity of different cells in various samples. D Dot plot showcasing the ligand-receptor pairs involved in communication between CAFs and other cells. E Heatmap indicating the importance of different cells in FGF signaling pathway networks. F Violin plot displaying the expression levels of FGF7 and FGFR2 in different cell types

Article Snippet: FGF7 levels in the supernatant of different groups were measured using a human FGF7 ELISA kit (R&D Systems, USA) following the manufacturer's instructions.

Techniques: Clinical Proteomics, Cell Counting, Expressing

Journal: Journal of Translational Medicine

Article Title: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter

doi: 10.1186/s12967-024-05085-y

Figure Lengend Snippet: Role of FGF7-FGFR2 signaling pathway and hypoxia in ovarian cancer progression. A Western blotting analysis of FGFR1-4 protein expression in OC cells treated with CAFs-CM. B Western blotting analysis of FGFR1-4 protein expression in OC cells treated with hFGF7 at concentrations of 10 ng/ml and 20 ng/ml. C Western blotting analysis of EMT marker protein expression in OC cells treated with CAFs-CM, FGF7-Ab, or FGFR2 antagonists. (D-E) Scatter plot illustrating the correlation between CAFs score from two algorithms and hypoxic pathway activation status. F Western blotting analysis of HIF-1α protein expression in OC cells treated with CAFs-CM, FGF7-Ab, or FGFR2 antagonists. G Schematic representation of HIF-1α protein ubiquitination. H Western blotting analysis of hydroxylated-HIF-1α and PHDs expression in OC cells treated with CAFs-CM or CAFs-CM pre-incubated with FGF7-Ab. I Co-immunoprecipitation of ubiquitin and pVHL with HIF1α in OC cells treated with CAFs-CM or CAFs-CM by preincubation with FGF7-Ab. J Western blotting analysis of HIF-1α protein expression in MG132-treated OC cells at different times. K Western blotting analysis of HIF-1α protein expression in OC cells treated with CAFs-CM or CAFs-CM pre-incubated with FGF7-Ab and MG132

Article Snippet: FGF7 levels in the supernatant of different groups were measured using a human FGF7 ELISA kit (R&D Systems, USA) following the manufacturer's instructions.

Techniques: Western Blot, Expressing, Marker, Activation Assay, Ubiquitin Proteomics, Incubation, Immunoprecipitation

Journal: Journal of Translational Medicine

Article Title: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter

doi: 10.1186/s12967-024-05085-y

Figure Lengend Snippet: FGF7 derived from CAFs promotes tumor growth in vivo. A The tumor xenografts were photographed on the 31st day of the experiment. B Tumor volumes were recorded every five days. C Tumor weights were measured at the end of the experiment. D Immunohistochemistry (IHC) analysis (n = 5). D The correlations between FGF7 and HIF-1α, FGFR2 IHC score in xenografts specimens were evaluated with Pearson correlation analysis (n = 5). E The correlations between FGF7 and ZEB1, Vimentin IHC score in xenografts specimens were evaluated with Pearson correlation analysis. (n = 5). F The correlations between FGF7 and E-cadherin, Ki-67 IHC score in xenografts specimens were evaluated with Pearson correlation analysis (n = 5). H – J The correlations between FGF7 and E-cadherin, ZEB1, FGFR2 IHC score in OC tissues were evaluated with Pearson correlation analysis. (n = 32). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Article Snippet: FGF7 levels in the supernatant of different groups were measured using a human FGF7 ELISA kit (R&D Systems, USA) following the manufacturer's instructions.

Techniques: Derivative Assay, In Vivo, Immunohistochemistry

Journal: Journal of Translational Medicine

Article Title: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter

doi: 10.1186/s12967-024-05085-y

Figure Lengend Snippet: Clinical correlation analysis of FGF7 in the TCGA-OV cohort

Article Snippet: FGF7 levels in the supernatant of different groups were measured using a human FGF7 ELISA kit (R&D Systems, USA) following the manufacturer's instructions.

Techniques:

Journal: Molecules

Article Title: Quercitrin Stimulates Hair Growth with Enhanced Expression of Growth Factors via Activation of MAPK/CREB Signaling Pathway

doi: 10.3390/molecules25174004

Figure Lengend Snippet: Effect of quercitrin on the protein expression of bFGF and KGF in cultured hDPCs. The DPCs were treated with quercitrin at concentrations of 1, 10, 100 nM and 1 µM for 24 h. Whole cell lysates ( a , c ) and culture medium ( b , d ) of each cultured DPCs were analyzed by ELISA to determine the levels of bFGF (a,b) and KGF (c,d). N.T, non-treated control. Significantly different compared with N.T (* p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: DPCs were treated with various concentrations of quercitrin for 24 h. The cells and culture medium were collected and the amounts of bFGF and KGF were measured using human bFGF and human KGF DuoSet ELISA (R&D systems) kits, according to the manufacturer’s instruction.

Techniques: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay, Control